Best Peptides for Energy (2026): MOTS-c, SS-31, NAD+ & More
Cellular energy production is the foundation of every biological process, and declining mitochondrial function is increasingly recognized as a central driver of fatigue, aging, and chronic disease. Peptides targeting mitochondrial health, metabolic efficiency, and hormonal optimization represent a new frontier in energy science. From MOTS-c's exercise-mimetic effects to SS-31's direct mitochondrial membrane stabilization, these compounds address fatigue at its root cause — cellular bioenergetics. This guide covers the evidence, mechanisms, and practical considerations for energy-focused peptide protocols. For a broader anti-aging approach, see the Anti-Aging Stack, or take the Peptide Finder Quiz to match compounds to your goals.
Last updated: 2026-03-03
Top Picks at a Glance
- 1.MOTS-c— Mitochondrial-derived peptide that activates AMPK and mimics exercise benefits
- 2.SS-31 (Elamipretide)— Mitochondrial-targeted peptide that stabilizes the inner membrane and restores electron transport
- 3.NAD+— Essential coenzyme for cellular energy production and DNA repair that declines with age
- 4.Ipamorelin— Selective GH secretagogue that supports energy through growth hormone optimization
How Peptides Support Cellular Energy Production
Understanding energy at the cellular level is essential for appreciating how peptides can address fatigue. Energy production occurs primarily in mitochondria through oxidative phosphorylation — the electron transport chain converts nutrients into ATP (adenosine triphosphate), the universal energy currency of cells. When mitochondrial function declines, every cell in the body produces less ATP, manifesting as fatigue, reduced exercise capacity, brain fog, and slow recovery.
Peptides address energy through several distinct mechanisms:
- Mitochondrial membrane stabilization: SS-31 directly binds cardiolipin in the inner mitochondrial membrane, restoring electron transport chain efficiency and reducing energy-wasting ROS production. This is the most direct approach to improving ATP output at the cellular level.
- Metabolic pathway activation: MOTS-c activates AMPK, the body's master energy sensor, triggering glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. This effectively tells cells to produce more energy and create new mitochondria to meet demand.
- Coenzyme replenishment: NAD+ is required for the electron transport chain, the TCA cycle, and over 500 enzymatic reactions. Replenishing declining NAD+ levels restores the biochemical machinery needed for energy production.
- Hormonal optimization: Ipamorelin stimulates growth hormone release, which supports fat metabolism (using stored fat for fuel), lean tissue maintenance, and cellular repair processes. GH deficiency is a major contributor to age-related fatigue.
- Mitochondrial biogenesis: Both MOTS-c (via AMPK/PGC-1alpha) and NAD+ (via SIRT1/PGC-1alpha) promote the creation of new mitochondria — increasing the total energy-producing capacity of cells.
Fatigue can also result from non-mitochondrial causes — thyroid dysfunction, anemia, depression, sleep disorders, chronic infection. These should be evaluated by a healthcare provider before attributing fatigue to mitochondrial decline. For sleep-related energy issues, see our sleep guide.
Energy Peptide Comparison Table
| Peptide | Energy Mechanism | Best For | Typical Dose | Evidence Level |
|---|---|---|---|---|
| MOTS-c | AMPK activation, exercise-mimetic | Metabolic fatigue, exercise capacity, aging | 5–10 mg SubQ, 3–5x/week | Preclinical + mechanistic |
| SS-31 | Cardiolipin stabilization, ETC repair | Mitochondrial dysfunction, heart failure, aging | 10–40 mg/day SubQ | Phase 2/3 clinical trials |
| NAD+ | Coenzyme replenishment, sirtuin activation | Age-related NAD+ decline, DNA repair, fatigue | 50–100 mg SubQ or 250–500 mg IV | Clinical + preclinical |
| Ipamorelin | GH optimization, body composition | GH-related fatigue, recovery, body composition | 200–300 mcg SubQ before bed | Clinical (GH secretagogue class) |
Note: SS-31 is the most clinically advanced mitochondrial peptide. MOTS-c offers the broadest metabolic effects. Use the peptide calculator for reconstitution volumes.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Understanding Mitochondrial Decline and Fatigue
Mitochondrial dysfunction is now recognized as a hallmark of aging and a contributor to virtually every chronic disease. Understanding why mitochondria decline helps explain why peptide-based interventions are being actively researched:
The vicious cycle of mitochondrial aging:
As mitochondria age, their electron transport chains become less efficient, leaking more electrons that form reactive oxygen species (ROS). These ROS damage mitochondrial DNA (which lacks the protective histones found in nuclear DNA), mitochondrial membranes, and the electron transport chain proteins themselves. This creates a vicious cycle: damaged mitochondria produce more ROS, which cause more damage, leading to progressive energy decline.
How peptides break this cycle:
- SS-31 interrupts the cycle at the membrane level — stabilizing cardiolipin prevents ROS overproduction at Complex III and IV of the electron transport chain, breaking the damage cascade at its source
- MOTS-c addresses the cycle at the cellular signaling level — AMPK activation triggers mitophagy (removal of damaged mitochondria) and biogenesis (creation of new, functional mitochondria), effectively replacing damaged with healthy
- NAD+ replenishes the coenzyme required for both energy production and the sirtuin-mediated repair pathways that maintain mitochondrial quality control
For broader aging-related health optimization, see our anti-aging guide and the longevity guide.
Peptides and Exercise Performance
Energy peptides show particular synergy with physical exercise because they target overlapping metabolic pathways:
MOTS-c and exercise: MOTS-c activates the same AMPK pathway that exercise stimulates. In aged mice, MOTS-c treatment improved physical performance metrics comparable to exercise training. This does not mean MOTS-c replaces exercise — rather, it may amplify the metabolic benefits of training and help maintain metabolic health when exercise capacity is limited (injury, illness, aging).
NAD+ and exercise recovery: Exercise depletes NAD+ through increased PARP activation (DNA repair from exercise-induced stress) and elevated metabolic demand. NAD+ supplementation may support faster recovery and maintain the cellular repair processes that drive exercise adaptations. Athletes report improved recovery times and sustained training capacity with NAD+ protocols.
GH secretagogues and training: Growth hormone is essential for post-exercise recovery, muscle protein synthesis, and fat metabolism during training. Ipamorelin enhances the natural GH response (which is also stimulated by exercise), potentially amplifying the recovery and body composition benefits of training.
SS-31 and endurance: By improving mitochondrial efficiency, SS-31 may enhance aerobic capacity and endurance performance. Clinical studies in older adults showed improved skeletal muscle mitochondrial function after SS-31 treatment.
For muscle-specific peptide applications, see our muscle growth guide and the Muscle Growth Stack.
Safety and Practical Considerations
Energy-focused peptides generally target fundamental metabolic processes, which demands careful consideration of dosing and monitoring:
MOTS-c: As an endogenous mitochondrial-derived peptide, MOTS-c is expected to have a favorable safety profile. The primary consideration is its hypoglycemic potential — by activating AMPK and increasing glucose uptake, it could lower blood sugar, particularly in individuals taking diabetes medications. Blood glucose monitoring is advisable during initial use.
SS-31: Clinical trial data from Phase 2/3 studies shows a generally well-tolerated profile. The most common side effects reported include injection site reactions and mild headache. Its highly targeted mechanism (cardiolipin binding) limits off-target effects. The ongoing clinical development provides the most rigorous safety data among energy peptides.
NAD+: IV NAD+ infusions can cause significant chest tightness, nausea, and flushing during rapid infusion — slowing the infusion rate typically resolves these effects. Subcutaneous NAD+ injection avoids these infusion-related symptoms. NAD+ activates PARPs, which consume NAD+ itself, so very high doses may paradoxically deplete other metabolic cofactors.
Ipamorelin: Well-studied GH secretagogue class. Side effects may include water retention, joint pain, and mild blood sugar elevation — consistent with GH elevation. Contraindicated in individuals with active cancer (GH can promote tumor growth) or a history of pituitary tumors. See the dosage guide for standard protocols.
Key recommendations:
- Rule out medical causes of fatigue (thyroid dysfunction, anemia, sleep apnea, depression) before attributing fatigue to mitochondrial decline
- Diabetics should monitor blood glucose closely with MOTS-c or other AMPK-activating compounds
- Start with one peptide at a time to assess individual response before combining
- Source from reputable suppliers with third-party COAs; follow proper reconstitution and storage procedures
Citations
- Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-454. PMID: 25738459
- Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." Br J Pharmacol. 2014;171(8):2029-2050. PMID: 26725645
- Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends Cell Biol. 2014;24(8):464-471. PMID: 26785480
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
- Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-771. PMID: 23692570
Energy Peptides: Detailed Breakdown
MOTS-c
MOTS-c (Mitochondrial ORF of the Twelve S rRNA Type-C) is a mitochondrial-derived peptide encoded within the mitochondrial genome. It is one of the most significant discoveries in mitochondrial biology in recent years — a peptide that directly links mitochondrial function to whole-body metabolic regulation through AMPK (AMP-activated protein kinase) activation.
MOTS-c has been called an "exercise mimetic" because it activates many of the same metabolic pathways triggered by physical exercise. It stimulates AMPK — the body's master energy sensor — which in turn activates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Research published in Cell Metabolism showed that MOTS-c treatment improved insulin sensitivity, increased fat oxidation, and enhanced exercise capacity in mice, particularly in aged animals where endogenous MOTS-c levels had declined (PMID: 25738459).
Key research findings:
- Activated AMPK signaling — the master switch for cellular energy metabolism
- Improved insulin sensitivity and glucose homeostasis in metabolically challenged mice
- Enhanced exercise capacity, particularly in aged animals with declining endogenous MOTS-c
- Increased fatty acid oxidation and metabolic efficiency
- Promoted mitochondrial biogenesis — the creation of new mitochondria
- Endogenous MOTS-c levels decline with age, correlating with metabolic dysfunction
MOTS-c is studied at 5–10 mg via subcutaneous injection, typically 3–5 times per week. See the complete MOTS-c guide for detailed protocols.
SS-31 (Elamipretide)
SS-31 (also known as Elamipretide or Bendavia) is a synthetic tetrapeptide that concentrates over 5,000-fold within mitochondria, specifically binding to cardiolipin in the inner mitochondrial membrane. Cardiolipin is a phospholipid critical for the structural integrity and function of the electron transport chain — the machinery that produces 90% of cellular ATP.
As cells age, cardiolipin becomes oxidized and disorganized, impairing electron transport efficiency, increasing reactive oxygen species (ROS) production, and reducing ATP output. SS-31 stabilizes cardiolipin-protein interactions, restoring electron transport chain function and reducing ROS leakage. Clinical trials have investigated SS-31 for heart failure, age-related mitochondrial dysfunction, and primary mitochondrial myopathy (PMID: 26725645).
Key research findings:
- Concentrated 5,000-fold within mitochondria through cardiolipin binding
- Restored electron transport chain efficiency in aged mitochondria
- Reduced mitochondrial ROS production — the primary source of cellular oxidative stress
- Improved ATP production in multiple organ systems (heart, skeletal muscle, brain, kidney)
- Phase 2/3 clinical trials for heart failure (Barth syndrome) and primary mitochondrial myopathy
- Reversed age-related declines in skeletal muscle mitochondrial function in clinical studies
SS-31 is studied at 10–40 mg daily via subcutaneous injection. It is one of the most clinically advanced mitochondrial-targeted peptides. See the complete SS-31 guide.
NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, serving as a critical electron carrier in the mitochondrial electron transport chain — the process that converts food into ATP (cellular energy). NAD+ also serves as a substrate for sirtuins (SIRT1-7) and PARPs — enzymes involved in DNA repair, gene expression regulation, and cellular stress response.
NAD+ levels decline approximately 50% between ages 40 and 60. This decline impairs mitochondrial function, reduces sirtuin activity, compromises DNA repair capacity, and contributes to the fatigue and metabolic dysfunction associated with aging. NAD+ restoration through supplementation (IV or subcutaneous injection) aims to reverse these age-related declines and restore cellular energy production capacity (PMID: 26785480).
Key research findings:
- NAD+ declines ~50% between ages 40–60, correlating with mitochondrial dysfunction
- NAD+ restoration improved mitochondrial function and exercise capacity in aged mice
- Activated SIRT1 and SIRT3 — sirtuins that regulate mitochondrial biogenesis and cellular stress response
- Enhanced DNA repair through PARP enzyme activation
- Human clinical trials show improved metabolic markers with NAD+ precursor supplementation
- Subjective improvements in energy, mental clarity, and recovery commonly reported
NAD+ is administered via IV infusion (250–500 mg over 2–4 hours) or subcutaneous injection (50–100 mg daily). Oral precursors (NMN, NR) are also used but have lower bioavailability.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor (GHS-R1a) without significantly affecting cortisol or prolactin — making it the "cleanest" GH secretagogue available. Growth hormone plays a crucial role in energy metabolism, body composition, and cellular repair processes that directly influence daily energy levels.
GH deficiency (which occurs progressively with aging — approximately 14% decline per decade after age 30) is associated with fatigue, reduced exercise capacity, increased body fat, and impaired recovery. By stimulating physiological GH pulses (maintaining natural feedback regulation), ipamorelin addresses these energy-related symptoms without the risks of exogenous GH administration. The resulting increase in IGF-1 supports mitochondrial function, glucose homeostasis, and lean tissue maintenance (PMID: 9849822).
Key research findings:
- Selective GH release without cortisol or prolactin elevation
- Maintained physiological GH pulsatility and feedback regulation
- Improved body composition (increased lean mass, reduced fat mass) in clinical studies
- Enhanced recovery from exercise and physical stress
- Improved sleep quality — GH is primarily released during deep sleep phases
- No appetite stimulation (unlike GHRP-6) — important for sustained energy without overeating
Ipamorelin is studied at 200–300 mcg via subcutaneous injection, typically before bedtime to align with natural GH release patterns. Often combined with CJC-1295 for synergistic effects. See the GH Optimization Stack.